An observational study in Thyroid Dysfunction, Hyperthyroidism and Cardiovascular Diseases, sponsored by First Affiliated Hospital Xi'an Jiaotong University. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by First Affiliated Hospital Xi'an Jiaotong University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Hyperthyroidism with a site in China — 4 open to participants now, 5 under way, none of them phase 3. Hyperthyroidism · China.
Among the 12 studies in Hyperthyroidism with a site in China, this one is the only one that started in 2026, is one of 8 observational ones, and was the 12th registered.
113 studies on the registry are indexed under Hyperthyroidism; 27 are open to participants now.
Browse Hyperthyroidism studies →4 of the 12 studies in Hyperthyroidism with a site in China are open now. Recruiting first, the newest first:
Chinese PLA General Hospital · Sites in China
Ages up to 80
Shengjing Hospital · Sites in China
Ages 29 days–14 yrs
The Second Affiliated Hospital of Jiaxing University · Sites in China
Ages 45–75
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 17 Hyperthyroidism studies recruiting now, 8 (47%) set no upper age limit and 7 (41%) stop at 75 or younger; 4 take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2
First in 2009; this study’s year is marked. 1 started in 2026.
This study's planned enrollment of 10,000 is above the median of 98 across 48 observational studies indexed under Hyperthyroidism.
Median enrollment 40 across the 4 interventional studies, 220 across the 8 observational. Of the 1 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 12 has an industry lead sponsor. The 10 most frequent:
First Affiliated Hospital Xi'an Jiaotong University is the lead sponsor of 317 studies on the registry; 90 are open to participants now.
First Affiliated Hospital Xi'an Jiaotong University has 1 study filed under Hyperthyroidism — fewer than ten, so there is no comparison to draw.
1 of the studies in Hyperthyroidism with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06570967Shengjing HospitalA Clinical Study of Hyperthyroidism in Children | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies in Hyperthyroidism with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this multicenter observational study is to investigate the relationship between thyroid function, changes in thyroid hormone levels over time, and cardiovascular diseases in adults. The main questions it aims to answer are:
Are different thyroid function states and long-term changes in thyroid hormone levels associated with the risk of major adverse cardiovascular events? How do thyroid function abnormalities affect cardiac structure and function, and can these changes improve after thyroid function returns to normal? Researchers will compare participants with normal thyroid function, subclinical thyroid dysfunction, and overt thyroid dysfunction to evaluate differences in cardiovascular outcomes.The study includes retrospective and prospective cohorts. Researchers will collect thyroid function tests, clinical records, electrocardiograms, echocardiographic findings, treatment information, and long-term cardiovascular outcomes. Participants in the prospective cohort will undergo follow-up, with biological samples collected for exploratory analyses when appropriate and with informed consent. No experimental treatments will be assigned.
The Thy-CVD Cohort is a nationwide, multicenter, observational study combining retrospective and prospective cohorts to investigate the associations of thyroid function abnormalities and dynamic thyroid hormone exposure with cardiac remodeling and long-term cardiovascular outcomes.The study will enroll adults aged 18 years or older with available thyroid function testing. Participants will be classified into five groups according to thyroid-stimulating hormone (TSH), free triiodothyronine (FT3), and free thyroxine (FT4) levels: euthyroidism, subclinical hyperthyroidism, overt hyperthyroidism, subclinical hypothyroidism, and overt hypothyroidism.The retrospective cohort will include patients evaluated between January 2018 and August 2026. The prospective cohort will enroll participants beginning in September 2026, with standardized longitudinal follow-up planned through 2036.Repeated thyroid function measurements will be used to evaluate the severity, duration, variability, and cumulative burden of thyroid hormone abnormalities, as well as the time required to achieve and maintain normal thyroid function.The primary outcome is the first occurrence of a composite major adverse cardiovascular event, including cardiovascular death, hospitalization for heart failure, myocardial infarction, ischemic or hemorrhagic stroke, and serious arrhythmias requiring clinical intervention.Secondary outcomes include individual cardiovascular events, all-cause mortality, and changes in cardiac structure and function assessed by serial echocardiography. The study will also investigate cardiac reverse remodeling and residual cardiovascular risk after normalization of thyroid function.Exploratory analyses will evaluate associations between thyroid treatment strategies, thyroid function control, and cardiovascular outcomes. Biological samples and clinically obtained residual cardiovascular tissues may be analyzed in selected participants to investigate potential molecular mechanisms.This is an observational study. All clinical treatments and examinations will be determined by treating physicians according to routine clinical practice, without investigator-assigned interventions.
Adults aged 18 years or older who undergo thyroid function testing at the First Affiliated Hospital of Xi'an Jiaotong University and participating medical centers across China. The study population includes individuals with normal thyroid function, subclinical hyperthyroidism, overt hyperthyroidism, subclinical hypothyroidism, and overt hypothyroidism. The retrospective cohort includes eligible patients identified from existing medical records between January 2018 and August 2026. The prospective cohort consecutively enrolls eligible participants beginning in September 2026 for longitudinal follow-up. Thyroid function status, cardiovascular risk factors, treatment information, cardiac imaging findings, and clinical outcomes will be collected. Biological sample availability is not required for enrollment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Biospecimen availability is not required for enrollment. Participants without available biological samples remain eligible if they meet the other inclusion and exclusion criteria.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adults aged 18 years or older who underwent thyroid function testing at participating centers between January 2018 and August 2026 will be retrospectively identified through existing electronic health records. Clinical data, including thyroid function measurements (TSH, FT3, and FT4), thyroid disease diagnoses, treatment history, cardiovascular risk factors, electrocardiographic and echocardiographic findings, and clinical outcomes, will be collected from existing medical records and follow-up databases. Participants will be classified according to baseline thyroid function status and longitudinal thyroid hormone exposure patterns, where repeated measurements are available. No additional clinical interventions will be performed.
Adults aged 18 years or older undergoing thyroid function testing at participating centers will be prospectively enrolled beginning in September 2026 and followed longitudinally. Baseline and follow-up data will include thyroid function measurements (TSH, FT3, and FT4), thyroid disease characteristics, treatment information, cardiovascular risk factors, electrocardiographic and echocardiographic findings, and clinical outcomes. Repeated thyroid function assessments will be used to characterize longitudinal hormone exposure patterns and their associations with cardiac remodeling and cardiovascular events. Biological samples may be collected with informed consent for exploratory analyses. Clinical management will follow routine medical practice without investigator-assigned interventions.
Time to First Major Adverse Cardiovascular Event (MACE)
Time from baseline to the first occurrence of major adverse cardiovascular events (MACE), defined as the composite of cardiovascular death, hospitalization for heart failure, myocardial infarction, ischemic or hemorrhagic stroke, or serious arrhythmia requiring clinical intervention, including new-onset atrial fibrillation and sustained ventricular arrhythmias. The outcome will be measured as time to the first qualifying event in days. Events will be identified through medical records, hospitalizations, clinical follow-up, and available death records. Only the first qualifying event per participant will be counted.
Time frame: Baseline; 3, 6, 12, 24, 36, 48, and 60 months; annually thereafter through 10 years of follow-up.
New-Onset Atrial Fibrillation
Number of participants without documented atrial fibrillation at baseline who develop newly diagnosed atrial fibrillation during follow-up. Atrial fibrillation will be identified by 12-lead electrocardiography, ambulatory electrocardiographic monitoring, or documented clinical diagnoses in medical records. The outcome will be reported as the number of participants with newly diagnosed atrial fibrillation.
Time frame: Baseline; 3, 6, 12, 24, 36, 48, and 60 months; annually thereafter through 10 years of follow-up.
Heart Failure Events
Number of participants experiencing clinically documented heart failure events during follow-up. Heart failure will be identified through physician-documented diagnoses, hospitalization records, and available clinical assessments. The outcome will be reported as the number of participants with documented heart failure events.
Time frame: Baseline; 3, 6, 12, 24, 36, 48, and 60 months; annually thereafter through 10 years of follow-up.
Coronary Artery Disease Events
Number of participants experiencing clinically documented coronary artery disease events during follow-up. Events will be identified from medical records, clinical diagnoses, coronary angiography, and available coronary imaging reports. The outcome will be reported as the number of participants with documented coronary artery disease events.
Time frame: Baseline; 3, 6, 12, 24, 36, 48, and 60 months; annually thereafter through 10 years of follow-up.
Start is estimated for Nov 2026; primary completion for Aug 2046, 236 months later.
Of 20 observational studies under Hyperthyroidism, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 48. This study's planned 236 months is above that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
First Affiliated Hospital Xi'an Jiaotong University →